News

With the in cell factory technology, living cells can be controlled and manipulated to make specific proteins with therapeutic benefits. Under the deal, MedImmune will provide funding and

The Yokebe is expected to generate about €30m in full year 2015 net sales. Yokebe comes in a shake/liquid form and is marketed within the ‘meal replacement’ category.

The company’s latest report* states that Stelara, an IL12/IL23 inhibitor, has demonstrated a strong safety profile in other indications, and is expected to launch in the US and

Ofatumumab is designed to target the CD20 molecule found on the surface of CLL cells and normal B lymphocytes. The sBLA, which was submitted by Novartis under Genmab’s

Lysogene and Alcyone Lifesciences will join forces to evaluate the intraparenchymal delivery of Lysogene’s proprietary rAAV to treat patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as

Simulations Plus will continue to provide licenses for its GastroPlus, ADMET Predictor, and MedChem Studio software programs for use by the DNTP/NIEHS. The DNTP within the NIEHS is

Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver’s ability to remove LDL-C, or "bad" cholesterol, from the blood. Elevated LDL-C is

The study findings, which are being presented in a late-breaking oral presentation at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, confirmed the antiretroviral

Neither the R&D goal that generated the milestone payment nor the amount were disclosed. The MvfR inhibitor program targets mechanisms of virulence and persistence in Pseudomonas and other